MYCN and neuroblastoma: The strong reduction of MYCN protein levels upon activation of the HIF2α pathway in MYCN-amplified cells coupled to the drop in proliferation and expression of noradrenergic genes (Fig. 4) indicate that rather than acting as a neuroblastoma oncogene, HIF2α has potential capacity to attenuate tumor growth.